M.et alHOPE and HOPE-TOO trial Investigators
led the Phase III trial, funded by the drugs maker, Novo Nordisk
Teenagers, for example, experience a period of hormonal change (puberty) where much of their caloric intake is directed toward protein synthesis and the production of muscle and bone
It raises the possibility that these drugs may have broader anti-inflammatory or cardiometabolic effects, which is particularly interesting in a systemic inflammatory disease such as HS. According to Jastrzb-Mikiewicz, patients with HS are frequently diagnosed with obesity, insulin resistance, diabetes, and other metabolic comorbidities, making GLP-1s particularly relevant for this population
This measures the percentage of the target peptide peak relative to other detectable peaks under specific analytical conditions